Study summary · research use only
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review summarizes literature from the past 5 years on analytical strategies to detect emerging and non-approved doping agents in human blood or urine. The abstract discusses low- and high-molecular-mass peptidic substances (such as modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604) and non-peptidic agents (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107, ARM036/aladorian) as well as inorganic cobalt, considering physicochemical properties, concentration levels, metabolism, and amenability to chromatographic-mass spectrometric or alternative detection methods, all classified as doping agents under World Anti-Doping Agency regulations.
Abstract
The number and diversity of potentially performance-enhancing substances is continuously growing, fueled by new pharmaceutical developments but also by the inventiveness and, at the same time, unscrupulousness of black-market (designer) drug producers and providers. In terms of sports drug testing, this situation necessitates reactive as well as proactive research and expansion of the analytical armamentarium to ensure timely, adequate, and comprehensive doping controls. This review summarizes literature published over the past 5 years on new drug entities, discontinued therapeutics, and 'tailored' compounds classified as doping agents according to the regulations of the World Anti-Doping Agency, with particular attention to analytical strategies enabling their detection in human blood or urine. Among these compounds, low- and high-molecular mass substances of peptidic (e.g. modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604, etc.) and non-peptidic (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107 and ARM036/aladorian, etc.) as well as inorganic (cobalt) nature are considered and discussed in terms of specific requirements originating from physicochemical properties, concentration levels, metabolism, and their amenability for chromatographic-mass spectrometric or alternative detection methods.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.